Psychometric Properties of the Apathy Scale in Advanced Parkinson's Disease.
Journal
Parkinson's disease
ISSN: 2090-8083
Titre abrégé: Parkinsons Dis
Pays: United States
ID NLM: 101539877
Informations de publication
Date de publication:
2019
2019
Historique:
received:
21
12
2018
revised:
18
02
2019
accepted:
03
03
2019
entrez:
30
4
2019
pubmed:
30
4
2019
medline:
30
4
2019
Statut:
epublish
Résumé
To assess the psychometric attributes of the Apathy Scale- (AS-) Spanish version in patients with advanced Parkinson's disease (APD). Over 6 months, 61 patients participated in a clinical study of levodopa-carbidopa intestinal gel (LCIG) and were evaluated using the AS and other clinical tools. Various psychometric attributes of the AS were assessed. Patients (60.7% men) were aged 68.02 ± 7.43 years, with 12.57 ± 5.97 years from PD diagnosis. Median HY of patients in "on state" was 2 (range, 1-4), and mean levodopa equivalent daily dose was 1455.98 ± 456.00 mg. Overall, the parameters of feasibility/acceptability were satisfactory, except for a moderate-to-high floor effect in AS items but not in its total score (both 3.3%). Cronbach's alpha was 0.78, while item homogeneity coefficient was 0.21. Almost all items (11/14) reached acceptable item-total corrected correlations ( The AS showed satisfactory feasibility, acceptability, scaling assumptions, internal consistency, and convergent validity. Responsiveness parameters were poor, probably due to the characteristics of the clinical study from which these data came. This trial is registered with NCT02289729.
Identifiants
pubmed: 31031906
doi: 10.1155/2019/1965394
pmc: PMC6458845
doi:
Banques de données
ClinicalTrials.gov
['NCT02289729']
Types de publication
Journal Article
Langues
eng
Pagination
1965394Références
J Neurol Neurosurg Psychiatry. 2002 Dec;73(6):636-42
pubmed: 12438462
J Clin Epidemiol. 2004 Jan;57(1):40-4
pubmed: 15019009
J Neurol Neurosurg Psychiatry. 2005 Jan;76(1):58-63
pubmed: 15607996
Parkinsonism Relat Disord. 2005 Jan;11(1):49-55
pubmed: 15619463
Cogn Behav Neurol. 2004 Dec;17(4):195-200
pubmed: 15622014
J Neuropsychiatry Clin Neurosci. 1992 Spring;4(2):134-9
pubmed: 1627973
J Neurol Neurosurg Psychiatry. 2006 May;77(5):579-84
pubmed: 16614016
Mov Disord. 2007 Oct 15;22(13):1901-11
pubmed: 17674410
Mov Disord. 2008 Oct 30;23(14):2004-14
pubmed: 18709683
Mov Disord. 2009 Nov 15;24(15):2175-86
pubmed: 19768724
Neurology. 2009 Nov 10;73(19):1584-91
pubmed: 19901251
J Geriatr Psychiatry Neurol. 2010 Mar;23(1):35-41
pubmed: 20015839
Psychiatry (Edgmont). 2007 Jul;4(7):28-37
pubmed: 20526405
Mov Disord. 2010 Nov 15;25(15):2649-53
pubmed: 21069833
Int J Geriatr Psychiatry. 2012 Feb;27(2):160-6
pubmed: 21462269
Age Ageing. 2011 Sep;40(5):614-21
pubmed: 21788252
Intern Med. 2011;50(15):1553-8
pubmed: 21804280
J Int Neuropsychol Soc. 2011 Nov;17(6):1058-66
pubmed: 22040900
Am J Geriatr Psychiatry. 2012 Feb;20(2):142-8
pubmed: 22064613
Parkinsonism Relat Disord. 2012 May;18(4):339-42
pubmed: 22166396
J Neuropsychiatry Clin Neurosci. 2012 Fall;24(4):463-71
pubmed: 23224453
J Parkinsons Dis. 2012;2(2):161-6
pubmed: 23939440
Acta Neurol Scand. 2015 Feb;131(2):80-7
pubmed: 25288130
Mov Disord. 2015 May;30(6):759-69
pubmed: 25787145
Lancet Neurol. 2015 May;14(5):518-31
pubmed: 25895932
Parkinsonism Relat Disord. 2015 Sep;21(9):1093-5
pubmed: 26228083
Mov Disord. 2016 May;31(5):625-31
pubmed: 26879133
J Phys Ther Sci. 2016 Jun;28(6):1724-7
pubmed: 27390403
Eur J Neurol. 2017 Jan;24(1):105-111
pubmed: 27670392
J Int Neuropsychol Soc. 2018 Mar;24(3):269-282
pubmed: 29032789
Parkinsonism Relat Disord. 2017 Dec;45:63-68
pubmed: 29037500
Brain. 2018 Feb 1;141(2):613-619
pubmed: 29329378
J Consult Clin Psychol. 1988 Dec;56(6):893-7
pubmed: 3204199
Gerontologist. 1980 Dec;20(6):649-55
pubmed: 7203086
Qual Life Res. 1995 Jun;4(3):241-8
pubmed: 7613534